MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
09 04 2019
Historique:
pubmed: 23 3 2019
medline: 23 5 2019
entrez: 23 3 2019
Statut: ppublish

Résumé

Activation of the Met receptor tyrosine kinase, either by its ligand, hepatocyte growth factor (HGF), or via ligand-independent mechanisms, such as

Identifiants

pubmed: 30898885
pii: 1819085116
doi: 10.1073/pnas.1819085116
pmc: PMC6462049
doi:

Substances chimiques

Antibodies, Bispecific 0
Antineoplastic Agents, Immunological 0
EPCAM protein, human 0
Epithelial Cell Adhesion Molecule 0
HGF protein, human 0
Hepatocyte Growth Factor 67256-21-7
MET protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-met EC 2.7.10.1

Banques de données

PDB
['6HYG', '6I07', '6I04']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7533-7542

Déclaration de conflit d'intérêts

Conflict of interest statement: Several authors are or were employees of Merrimack Pharmaceuticals, Inc. at the time of contributing to the manuscript.

Références

J Natl Cancer Inst. 2011 Apr 20;103(8):645-61
pubmed: 21464397
Cancer Cell Int. 2010 Nov 02;10:44
pubmed: 21044305
Carcinogenesis. 2010 Nov;31(11):1913-21
pubmed: 20837599
J Mol Biol. 2014 Feb 6;426(3):630-44
pubmed: 24211234
Cancer Cell. 2003 Apr;3(4):347-61
pubmed: 12726861
Nat Chem Biol. 2014 Jul;10(7):567-73
pubmed: 24859116
Protein Eng. 1996 Jul;9(7):617-21
pubmed: 8844834
Oncogene. 1995 Feb 16;10(4):739-49
pubmed: 7862451
J Mol Biol. 2014 May 1;426(9):1947-57
pubmed: 24576605
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4477-82
pubmed: 15070743
Cancer Discov. 2016 Dec;6(12):1334-1341
pubmed: 27694386
Methods. 2014 Jan 1;65(1):95-104
pubmed: 23872324
J Cell Sci. 1998 Jan;111 ( Pt 2):237-47
pubmed: 9405310
Mol Cancer Ther. 2013 Dec;12(12):2748-59
pubmed: 24132142
J Clin Oncol. 2017 Feb;35(4):412-420
pubmed: 27937096
Ther Adv Med Oncol. 2011 Nov;3(1 Suppl):S7-S19
pubmed: 22128289
BMC Cancer. 2016 Feb 16;16:105
pubmed: 26879245
PLoS One. 2015 Oct 07;10(10):e0139679
pubmed: 26445503
Acta Crystallogr D Biol Crystallogr. 2008 Jun;64(Pt 6):700-4
pubmed: 18560159
Mol Immunol. 2014 Nov;62(1):46-53
pubmed: 24956411
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Cancer Lett. 2008 Jul 8;265(2):258-69
pubmed: 18395971
EMBO J. 2004 Jun 16;23(12):2325-35
pubmed: 15167892
J Clin Oncol. 2011 Dec 20;29(36):4803-10
pubmed: 22042947
Mol Cell Biol. 1992 Nov;12(11):5152-8
pubmed: 1406687
Ann Thorac Surg. 1998 Dec;66(6):1915-8
pubmed: 9930468
Transl Lung Cancer Res. 2012 Sep;1(3):179-93
pubmed: 25806180
Mol Cancer Ther. 2020 May;19(5):1210-1217
pubmed: 32127466
Bioinformatics. 2015 Nov 1;31(21):3558-60
pubmed: 26142188
J Thorac Oncol. 2010 Mar;5(3):305-13
pubmed: 20107422
Nature. 2015 Jun 18;522(7556):349-53
pubmed: 25985180
Proc Natl Acad Sci U S A. 1979 Mar;76(3):1438-42
pubmed: 286328
Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48
pubmed: 21102609
Clin Cancer Res. 2014 Dec 01;20(23):6059-70
pubmed: 25231402
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
MAbs. 2013 Mar-Apr;5(2):237-54
pubmed: 23392215
Clin Cancer Res. 2017 Apr 15;23(8):1910-1919
pubmed: 27803065
Invest New Drugs. 2014 Apr;32(2):355-61
pubmed: 24337769
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
pubmed: 18093943
Cancer Res. 2013 May 15;73(10):3087-96
pubmed: 23598276
Nat Commun. 2014 Aug 28;5:4764
pubmed: 25163760
Oncogene. 2006 Jan 19;25(3):409-18
pubmed: 16186806
Cancer Cell. 2010 Jan 19;17(1):77-88
pubmed: 20129249
Biochim Biophys Acta. 2013 Aug;1828(8):1989-2001
pubmed: 23618806
J Biol Chem. 1994 Apr 29;269(17):12846-51
pubmed: 8175699
J Biol Chem. 2010 Nov 12;285(46):36149-57
pubmed: 20833723
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
Nucleic Acids Res. 2005 Apr 22;33(7):2302-9
pubmed: 15849316
J Clin Oncol. 2013 Nov 10;31(32):4105-14
pubmed: 24101053
J Virol. 2014 Jun;88(12):7083-92
pubmed: 24719426
Nat Rev Drug Discov. 2008 Jun;7(6):504-16
pubmed: 18511928
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96
pubmed: 23882082
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
Cancer Res. 2014 Nov 15;74(22):6598-609
pubmed: 25217525
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11026-31
pubmed: 20534479
Cancer Res. 1999 Nov 15;59(22):5758-67
pubmed: 10582696
Br J Cancer. 1998 Dec;78(11):1407-16
pubmed: 9836471
Cancer Res. 2016 Jul 1;76(13):3942-53
pubmed: 27216193
Int J Cancer. 2006 Aug 1;119(3):477-83
pubmed: 16453287
J Clin Oncol. 2015 Aug 20;33(24):2667-74
pubmed: 26169611
J Clin Oncol. 2011 Aug 20;29(24):3307-15
pubmed: 21768463
Cancer Discov. 2013 Jun;3(6):658-73
pubmed: 23729478
Cancer. 1999 May 1;85(9):1894-902
pubmed: 10223227

Auteurs

Jessica B Casaletto (JB)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Melissa L Geddie (ML)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Adnan O Abu-Yousif (AO)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Kristina Masson (K)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Aaron Fulgham (A)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Antoine Boudot (A)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Tim Maiwald (T)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Jeffrey D Kearns (JD)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Neeraj Kohli (N)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Stephen Su (S)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Maja Razlog (M)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Andreas Raue (A)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139; araue@merrimack.com gavin.macbeath@gmail.com.

Ashish Kalra (A)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Maria Håkansson (M)

SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden.

Derek T Logan (DT)

SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden.

Martin Welin (M)

SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden.

Shrikanta Chattopadhyay (S)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Brian D Harms (BD)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Ulrik B Nielsen (UB)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Birgit Schoeberl (B)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Alexey A Lugovskoy (AA)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139.

Gavin MacBeath (G)

Discovery Division, Merrimack Pharmaceuticals, Inc., Cambridge, MA 02139; araue@merrimack.com gavin.macbeath@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH